Objectives Tumor mutational burden is an emerging biomarker of response to immune
checkpoint inhibitors (ICI), whose clinical adoption is challenging. We hypothesized that …

Inhibitors of the PD-1/PD-L1/CTLA-4 immune checkpoint pathway have revolutionized
cancer treatment. Indeed, some patients with advanced, refractory malignancies achieve …

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …

Purpose: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced
driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Purpose: We evaluated the predictive value of pretreatment ctDNA to inform therapeutic
outcomes in patients with metastatic melanoma relative to type and line of treatment …

Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid
tumors with dramatic and durable responses seen across multiple tumor types. However …

Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent
treatment strongly predicts recurrence in multiple tumor types, but whether further treatment …

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to
immunotherapy. BR. 36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of …

PURPOSE Identification of predictors for overall survival (OS) allows timely detection of
clinical efficacy signals and therefore facilitates treatment decisions. We assessed the …